SCHEMBL18554131

SCHEMBL18554131

CCOC(=O)CCCCCOc1cc([N+](=O)[O-])c(C=O)cc1OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.57
MAPT P10636 6/20 0.57
KDM4E B2RXH2 3/20 0.57
CYP3A4 P08684 2/20 0.57
ALOX15 P16050 1/20 0.57
PRKDC P78527 1/20 0.57
HSD17B10 Q99714 1/20 0.57
TDP1 Q9NUW8 1/20 0.50
TNF P01375 4/20 0.49
HPGD P15428 2/20 0.44
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HTT P42858 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.42
CYP2C19 P33261 2/20 0.41
CYP1A2 P05177 1/20 0.41
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18953087 0.96 ALDH1A1 (0.60) ALDH1A1MAPTKDM4ECYP3A4ALOX15
SCHEMBL16397986 0.90 ALDH1A1 (0.55) ALDH1A1MAPTKDM4ECYP3A4ALOX15
SCHEMBL7309433 0.89 ALDH1A1 (0.44) ALDH1A1MAPTKDM4ECYP3A4ALOX15
SCHEMBL10376957 0.88 ALDH1A1 (0.45) ALDH1A1MAPTKDM4ECYP3A4ALOX15
SCHEMBL7307312 0.87 ALDH1A1 (0.42) ALDH1A1MAPTKDM4ECYP3A4ALOX15
SCHEMBL7315056 0.86 MAPT (0.43) ALDH1A1MAPTKDM4ECYP3A4ALOX15
SCHEMBL7316885 0.86 MAPT (0.43) ALDH1A1MAPTKDM4ECYP3A4ALOX15
SCHEMBL32690661 0.85 ALDH1A1 (0.64) ALDH1A1MAPTKDM4ECYP3A4ALOX15
SCHEMBL32690685 0.85 ALDH1A1 (0.64) ALDH1A1MAPTKDM4ECYP3A4ALOX15
SCHEMBL3942989 0.85 ALDH1A1 (0.64) ALDH1A1MAPTKDM4ECYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12583857-B2 Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines PHEON THERAPEUTICS LTD (GB) 2026-03-24 US disclosed
US-20250011317-A1 ANTI-PROLIFERATIVE AGENTS PHEON THERAPEUTICS LTD (GB) 2025-01-09 US disclosed
US-11912700-B2 Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines PHEON THERAPEUTICS LTD (GB) 2024-02-27 US disclosed
US-11912700-B2 Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines PHEON THERAPEUTICS LTD (GB) 2024-02-27 US disclosed
US-11912700-B2 Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines PHEON THERAPEUTICS LTD (GB) 2024-02-27 US disclosed
US-20240002379-A1 ASYMMETRIC CONJUGATE COMPOUNDS PHEON THERAPEUTICS LTD (GB) 2024-01-04 US disclosed
EP-4086251-A1 PIPERIDINOBENZODIAZEPINE COMPOUNDS WITH ANTI PROLIFERATIVE ACTIVITY Femtogenix Limited (GB) 2022-11-09 EP disclosed
CN-114907345-A Piperidine-benzodiazepine compound having anti-proliferative activity 福姆通格尼克斯有限公司 2022-08-16 CN disclosed
EP-3337795-B1 PIPERIDINOBENZODIAZEPINE COMPOUNDS WITH ANTI PROLIFERATIVE ACTIVITY FEMTOGENIX LTD (GB) 2022-06-22 EP disclosed
EP-3337795-B1 PIPERIDINOBENZODIAZEPINE COMPOUNDS WITH ANTI PROLIFERATIVE ACTIVITY FEMTOGENIX LTD (GB) 2022-06-22 EP disclosed
US-20190144443-A1 ASYMMETRIC CONJUGATE COMPOUNDS PHEON THERAPEUTICS LTD (GB) 2019-05-16 US disclosed
US-20190144443-A1 ASYMMETRIC CONJUGATE COMPOUNDS PHEON THERAPEUTICS LTD (GB) 2019-05-16 US disclosed
EP-3455225-A1 ASYMMETRIC CONJUGATE COMPOUNDS Femtogenix Limited (GB) 2019-03-20 EP disclosed
US-20180339985-A1 PDD COMPOUNDS FEMTOGENIX LIMITED (GB) 2018-11-29 US disclosed
US-20180291021-A1 PDD COMPOUNDS PHEON THERAPEUTICS LTD (GB) 2018-10-11 US disclosed
EP-3337795-A1 PIPERIDINOBENZODIAZEPINE COMPOUNDS WITH ANTI PROLIFERATIVE ACTIVITY Femtogenix Limited (GB) 2018-06-27 EP disclosed
WO-2017194960-A1 ASYMMETRIC CONJUGATE COMPOUNDS FEMTOGENIX LIMITED (GB) 2017-11-16 WO disclosed
WO-2017194960-A1 ASYMMETRIC CONJUGATE COMPOUNDS FEMTOGENIX LIMITED (GB) 2017-11-16 WO disclosed
WO-2017032983-A1 PIPERIDINOBENZODIAZEPINE COMPOUNDS WITH ANTI PROLIFERATIVE ACTIVITY FEMTOGENIX LIMITED (GB) 2017-03-02 WO disclosed
WO-2017032983-A1 PIPERIDINOBENZODIAZEPINE COMPOUNDS WITH ANTI PROLIFERATIVE ACTIVITY FEMTOGENIX LIMITED (GB) 2017-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583857-B2 Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines CNR1, MTNR1B, MTNR1A ALDH1A1 1463/4885MAPT 3224/4885KDM4E 1922/4885
US-20250011317-A1 ANTI-PROLIFERATIVE AGENTS CCND2, BRD2, CCND3 ALDH1A1 3182/4885MAPT 4580/4885KDM4E 1454/4885
US-20240002379-A1 ASYMMETRIC CONJUGATE COMPOUNDS TUBA1C, MTX2, CCNO ALDH1A1 2285/4885MAPT 410/4885KDM4E 3451/4885
US-20180291021-A1 PDD COMPOUNDS DRD1, DRD3, DRD2 ALDH1A1 3010/4885MAPT 3769/4885KDM4E 2551/4885
US-20190144443-A1 ASYMMETRIC CONJUGATE COMPOUNDS TUBA1C, MTX2, CCNO ALDH1A1 2302/4885MAPT 424/4885KDM4E 3476/4885
US-11912700-B2 Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines MKI67, CCND2, CCND1 ALDH1A1 443/4885MAPT 2106/4885KDM4E 684/4885
US-20180339985-A1 PDD COMPOUNDS DRD1, DRD3, DRD2 ALDH1A1 2727/4885MAPT 3926/4885KDM4E 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.